1. Home
  2. ANAB vs FOR Comparison

ANAB vs FOR Comparison

Compare ANAB & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$64.27

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$25.26

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
FOR
Founded
2005
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
ANAB
FOR
Price
$64.27
$25.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$70.60
$31.75
AVG Volume (30 Days)
439.6K
118.1K
Earning Date
05-25-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
91.02
N/A
EPS
N/A
0.30
Revenue
$234,603,000.00
$1,662,400,000.00
Revenue This Year
N/A
$0.52
Revenue Next Year
$43.04
$7.72
P/E Ratio
N/A
$83.10
Revenue Growth
157.01
10.14
52 Week Low
$15.32
$18.00
52 Week High
$66.66
$30.74

Technical Indicators

Market Signals
Indicator
ANAB
FOR
Relative Strength Index (RSI) 66.99 35.01
Support Level $43.67 $25.25
Resistance Level N/A $26.00
Average True Range (ATR) 3.71 0.88
MACD 0.75 -0.45
Stochastic Oscillator 86.73 19.61

Price Performance

Historical Comparison
ANAB
FOR

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

Share on Social Networks: